DK3325623T6 - Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft - Google Patents

Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft Download PDF

Info

Publication number
DK3325623T6
DK3325623T6 DK16744699.6T DK16744699T DK3325623T6 DK 3325623 T6 DK3325623 T6 DK 3325623T6 DK 16744699 T DK16744699 T DK 16744699T DK 3325623 T6 DK3325623 T6 DK 3325623T6
Authority
DK
Denmark
Prior art keywords
cancer
combination
parp inhibitors
dbait molecule
dbait
Prior art date
Application number
DK16744699.6T
Other languages
English (en)
Other versions
DK3325623T3 (da
Inventor
Marie Dutreix
Wael Jdey
Original Assignee
Inst Curie
Centre Nat Rech Scient
Onxeo
Inst Nat Sante Rech Med
Univ Paris Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56551383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3325623(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Curie, Centre Nat Rech Scient, Onxeo, Inst Nat Sante Rech Med, Univ Paris Saclay filed Critical Inst Curie
Application granted granted Critical
Publication of DK3325623T3 publication Critical patent/DK3325623T3/da
Publication of DK3325623T6 publication Critical patent/DK3325623T6/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
DK16744699.6T 2015-07-23 2016-07-22 Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft DK3325623T6 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306201 2015-07-23
EP16166674 2016-04-22
PCT/EP2016/067479 WO2017013237A1 (en) 2015-07-23 2016-07-22 Use of a combination of dbait molecule and parp inhibitors to treat cancer

Publications (2)

Publication Number Publication Date
DK3325623T3 DK3325623T3 (da) 2019-08-19
DK3325623T6 true DK3325623T6 (da) 2021-03-15

Family

ID=56551383

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19177392.8T DK3594343T3 (da) 2015-07-23 2016-07-22 Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
DK16744699.6T DK3325623T6 (da) 2015-07-23 2016-07-22 Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19177392.8T DK3594343T3 (da) 2015-07-23 2016-07-22 Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft

Country Status (17)

Country Link
US (2) US10563197B2 (da)
EP (2) EP3594343B1 (da)
JP (1) JP6457696B2 (da)
KR (1) KR101896567B1 (da)
CN (1) CN108138177B9 (da)
AU (1) AU2016296905B2 (da)
CA (1) CA2993270C (da)
DK (2) DK3594343T3 (da)
ES (2) ES2879434T3 (da)
HK (1) HK1248281B (da)
HU (1) HUE045916T2 (da)
IL (1) IL256799A (da)
LT (1) LT3325623T (da)
PL (1) PL3325623T6 (da)
PT (1) PT3325623T (da)
SI (1) SI3325623T1 (da)
WO (1) WO2017013237A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709076D0 (en) * 2017-06-07 2017-07-19 Inst Of Cancer Research: Royal Cancer Hospital Parp inhibitors for use in methods of treating cancer
EP3461488A1 (en) * 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
KR20200130856A (ko) * 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CN113166762A (zh) * 2018-12-21 2021-07-23 欧恩科斯欧公司 新的偶联核酸分子及其用途
CN114364798A (zh) * 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
AU2020244809A1 (en) * 2019-03-25 2021-10-07 Cyteir Therapeutics, Inc. Combinations of RAD51 and PARP inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL286445A1 (en) 1989-08-11 1991-04-22 Ici Plc Method of obtaining novel quinoline derivatives
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
AU7759291A (en) 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
US5843643A (en) 1992-02-21 1998-12-01 Ratner; Paul L. Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
US5646042A (en) 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
AU6011496A (en) 1995-06-08 1997-01-09 Therexsys Limited Improved pharmaceutical compositions for gene therapy
AUPN741696A0 (en) 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
CA2302316A1 (en) 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
NZ512731A (en) 1999-01-11 2004-01-30 Agouron Pharma Tricyclic inhibitors of poly(ADP-ribose) polymerases
EP1142881A4 (en) 1999-01-14 2003-05-07 Meiji Seika Kaisha POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
JP2003510328A (ja) 1999-09-28 2003-03-18 ビーエーエスエフ アクチェンゲゼルシャフト アゼピノインドール誘導体、その製法ならびに使用
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6444676B1 (en) 1999-12-20 2002-09-03 Iok-Hou Pang Use of PARP inhibitors in the treatment of glaucoma
ES2290115T3 (es) 2000-02-01 2008-02-16 ABBOTT GMBH & CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
AU2001248748A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
WO2001091796A2 (en) 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
EP1330442B1 (en) 2000-10-30 2011-01-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
WO2002044183A2 (en) 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2002044157A2 (en) 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
JP3935363B2 (ja) 2001-06-26 2007-06-20 サカタインクス株式会社 水性顔料分散体の製造方法およびその方法から得られる水性顔料分散体
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003014121A1 (en) 2001-08-07 2003-02-20 Guilford Pharmaceuticals Inc. Compounds, derivatives, compositions, preparation and uses
WO2003015785A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
WO2003051879A1 (en) 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
AU2003277674A1 (en) 2002-11-12 2004-06-03 Mochida Pharmaceutical Co., Ltd. Novel parp inhibitors
TW200412959A (en) 2002-11-22 2004-08-01 Mitsubishi Pharma Corp Isoquinoline compounds and medicinal use thereof
MXPA05009661A (es) 2003-03-12 2006-03-08 Kudos Pharm Ltd Derivados de ftalazinona.
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
HU227948B1 (en) 2003-04-30 2012-07-30 Pecsi Tudomanyegyetem Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
AU2004242947B2 (en) 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
WO2004108723A1 (en) 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors
PT1660095E (pt) 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
BRPI0414171A (pt) 2003-09-04 2006-10-31 Warner Lambert Co benzo[b]tiofenos halossubstituìdos com atividade inibidora de pi3k como agentes terapêuticos
US7405300B2 (en) 2003-09-04 2008-07-29 Aventis Pharmaveuticals Inc. Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
EP1526177A1 (en) 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality
US7476729B2 (en) 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
MXPA06005686A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
KR101159118B1 (ko) 2003-12-05 2012-06-22 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-치환된2-퀴놀리논 및 2-퀴녹살리논
US7652014B2 (en) 2003-12-10 2010-01-26 Janssen Pharmaceutica Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
DE202004003061U1 (de) 2004-02-25 2005-07-14 Kronospan Technical Company Ltd., Engomi Dekorpapier mit elektrisch geladenen Fasern
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005108400A1 (ja) 2004-05-11 2005-11-17 Mochida Pharmaceutical Co. Ltd. 二環系へテロ環で置換されたピリドキナゾリン誘導体
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
EP1763523B1 (en) 2004-06-30 2013-03-20 Janssen Pharmaceutica NV Quinazolinedione derivatives as parp inhibitors
MXPA06014542A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de poli(adp-ribosa) polimerasa-i.
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
WO2006008118A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
NZ553201A (en) 2004-09-22 2010-09-30 Pfizer Method of preparing poly(ADP-ribose) polymerases inhibitors
EP1799685B1 (en) 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
NZ553295A (en) 2004-09-22 2010-04-30 Pfizer Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
DE102004050196A1 (de) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20060128777A1 (en) 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
JP4932735B2 (ja) 2004-12-17 2012-05-16 アムジエン・インコーポレーテツド アミノピリミジン化合物および使用方法
US20060204981A1 (en) 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
WO2006078711A2 (en) 2005-01-19 2006-07-27 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
RU2008100017A (ru) 2005-06-10 2009-07-20 Бипар Сайенсиз, Инк. (Us) Модуляторы parp и способ лечения рака
JPWO2006137510A1 (ja) 2005-06-24 2009-01-22 小野薬品工業株式会社 脳血管障害時における出血低減剤
NZ565654A (en) 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
CN101316834A (zh) 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2007144637A1 (en) 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
JP2009539963A (ja) 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤
WO2007144639A1 (en) 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
WO2008015429A2 (en) 2006-08-01 2008-02-07 Sentinel Oncology Limited Pharmaceutical compounds
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
EP1944369A1 (en) 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
CA2680549A1 (en) 2007-03-12 2008-09-18 Alan D. D'andrea Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
CA2687786A1 (en) 2007-05-25 2008-12-04 Astrazenca Ab Combination of chk and parp inhibitors for the treatment of cancers
SG185272A1 (en) 2007-10-03 2012-11-29 Eisai Inc Parp inhibitor compounds, compositions and methods of use
WO2009063998A1 (ja) 2007-11-14 2009-05-22 Ribomic Inc. 疎水性物質付加核酸及びその使用
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
SA109300394B1 (ar) 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
JP2012509258A (ja) 2008-11-17 2012-04-19 エンゾン ファーマシューティカルズ，インコーポレーテッド 核酸送達系のための分岐カチオン性脂質
WO2010082813A1 (en) 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
KR20110113648A (ko) 2009-02-04 2011-10-17 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료
PL3135301T3 (pl) * 2010-06-22 2018-11-30 Onxeo Zoptymalizowany system dostarczania in vivo z czynnikami andosomolitycznymi koniugatów kwasów nukleinowych
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US9670547B2 (en) 2010-09-15 2017-06-06 Almac Diagnostics Limited Molecular diagnostic test for cancer
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
RU2013150102A (ru) 2011-04-11 2015-05-20 Эббви Инк. Ингибиторы parp для лечения cipn
EP2527440A1 (en) * 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
MX2014009892A (es) * 2012-02-17 2015-02-12 Pharmacyclics Inc Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas.
MA37808A1 (fr) 2012-06-27 2018-03-30 Alzheimers Institute Of America Inc Composés et leurs utilisations thérapeutiques
EP2918292B1 (en) 2012-11-08 2019-12-11 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
CN104003979B (zh) 2013-02-21 2016-08-17 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途
WO2014170441A1 (en) * 2013-04-19 2014-10-23 Dna Therapeutics Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules
CN104140426B (zh) 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN104230896A (zh) 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
PT3325623T (pt) 2019-09-04
JP2018521072A (ja) 2018-08-02
CN108138177B9 (zh) 2021-08-13
KR101896567B1 (ko) 2018-09-07
SI3325623T1 (sl) 2019-11-29
PL3325623T6 (pl) 2022-05-30
KR20180051500A (ko) 2018-05-16
ES2742197T3 (es) 2020-02-13
CN108138177B (zh) 2019-03-19
JP6457696B2 (ja) 2019-01-23
EP3325623B1 (en) 2019-06-05
EP3325623A1 (en) 2018-05-30
EP3594343A1 (en) 2020-01-15
CN108138177A (zh) 2018-06-08
ES2879434T3 (es) 2021-11-22
WO2017013237A1 (en) 2017-01-26
US10563197B2 (en) 2020-02-18
DK3594343T3 (da) 2021-06-28
LT3325623T (lt) 2019-10-25
PL3325623T3 (pl) 2019-12-31
HUE045916T2 (hu) 2020-01-28
CA2993270C (en) 2019-07-16
IL256799A (en) 2018-02-28
AU2016296905B2 (en) 2018-07-05
US20200172901A1 (en) 2020-06-04
AU2016296905A1 (en) 2018-02-08
US11162095B2 (en) 2021-11-02
EP3325623B3 (en) 2021-01-20
US20180362972A1 (en) 2018-12-20
HK1248281B (zh) 2020-06-05
CA2993270A1 (en) 2017-01-26
DK3325623T3 (da) 2019-08-19
EP3594343B1 (en) 2021-04-21
ES2742197T7 (es) 2021-10-06

Similar Documents

Publication Publication Date Title
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3445767T3 (da) Makrocykliske mcl1-inhibitorer til behandling af cancer
DK3371171T3 (da) Inhibitorer af RET
DK3594343T3 (da) Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3377059T3 (da) Hæmmere af cxcr2
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3442972T3 (da) Bromdomænehæmmere
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3423451T3 (da) Inhibitorer af wdr5-protein-proteinbinding
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3227310T3 (da) Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3122358T3 (da) Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3157566T3 (da) Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3534885T3 (da) Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46193A (fr) Inhibiteurs hétéroaryles de pad4
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase